Medrx Co

Medrx Co FCF per Share

The Free Cash Flow per Share of Medrx Co (4586.T) as of Nov 19, 2026 is -15.04 JPY. In the previous year, Free Cash Flow per Share was -16.91 JPY — a change of -11.08% (higher).

FCF per Share

-15.04JPY

YoY

-11.08%

Last updated:

Free Cash Flow per Share of Medrx Co is 2025 -15.04 JPY. Free Cash Flow per Share of Medrx Co was 2024 -16.91 JPY. It decreases by -11.08% higher compared to the previous year.

The Medrx Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-127.63 JPY
Jan 1, 2019
-139.60 JPY
Jan 1, 2020
-56.06 JPY
Jan 1, 2021
-39.10 JPY
Jan 1, 2022
-38.10 JPY
Jan 1, 2023
-23.82 JPY
Jan 1, 2024
-16.91 JPY
Jan 1, 2025
-15.04 JPY
The Medrx Co FCF per Share history
YEARFCF per ShareYoY
-15.04JPY-11.08%
-16.91JPY-28.99%
-23.82JPY-37.48%
-38.10JPY-2.57%
-39.10JPY-30.26%
-56.06JPY-59.84%
-139.60JPY+9.39%
-127.63JPY+23.40%
-103.42JPY-27.93%
-143.50JPY+933.09%
-13.89JPY-20.56%
-17.49JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Free Cash Flow per Share of Medrx Co is -15.04 JPY in 2025.

Free Cash Flow per Share of Medrx Co changed from -16.91 JPY to -15.04 JPY, representing a -11.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Medrx Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medrx Co

All Key Metrics — Medrx Co